Zytiga and Thrombocytopenia - a phase IV clinical study of FDA data

Summary:

Thrombocytopenia is reported as a side effect among people who take Zytiga (abiraterone acetate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Xtandi, and have Prostate cancer.

The phase IV clinical study analyzes which people have Thrombocytopenia when taking Zytiga. It is created by eHealthMe based on reports of 29,870 people who have side effects when taking Zytiga from the FDA, and is updated regularly.

What is Zytiga?

Zytiga has active ingredients of abiraterone acetate. It is often used in prostate cancer metastatic. eHealthMe is studying from 29,928 Zytiga users. Check the latest studies of Zytiga.

What is Thrombocytopenia?

Thrombocytopenia (decrease of platelets in blood) is found to be associated with 2,789 drugs and 4,873 conditions by eHealthMe. Check the latest studies of Thrombocytopenia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

29,870 people reported to have side effects when taking Zytiga.
Among them, 364 people (1.22%) have Thrombocytopenia.

Among these 364 people:

* Approximation only. Some reports may have incomplete information.

Do you take Zytiga and have Thrombocytopenia?

- Check whether Thrombocytopenia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zytiga:

Zytiga (29,928 reports)

Thrombocytopenia treatments and more:

Thrombocytopenia (285,083 reports)

How severe was Thrombocytopenia and when was it recovered:

Thrombocytopenia in Zytiga

Expand to all the drugs that have ingredients of abiraterone acetate:

Thrombocytopenia and drugs with ingredients of abiraterone acetate (623 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zytiga:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Thrombocytopenia:

Thrombocytopenia (2,789 drugs)

Browse all the conditions that are associated with Thrombocytopenia:

Thrombocytopenia (4,873 conditions)

Related publications that referenced our studies

YavasogluI, I., TurgutkayaII, A., & BolamanIII, Z., "Chlorella-induced thrombocytopenia", DATA, 2018 Jan .
Rasmy A, Rahal M, Kisana M, Ahmad S, Salah A, "Morphine induced thrombocytopenia: A case report", Journal of Case Reports and Images in Oncology, 2015 Dec .
Onder H, Arsava EM, Arat A, Topcuoglu MA, "Acute middle cerebral artery occlusion treated by thrombectomy in a patient with myelodysplastic syndrome and severe thrombocytopenia", Journal of vascular and interventional neurology, 2015 Jan .
YavasogluI, I., TurgutkayaII, A., & BolamanIII, Z., "Chlorella-induced thrombocytopenia", DATA, 2018 Jan .
Rasmy A, Rahal M, Kisana M, Ahmad S, Salah A, "Morphine induced thrombocytopenia: A case report", Journal of Case Reports and Images in Oncology, 2015 Dec .
Onder H, Arsava EM, Arat A, Topcuoglu MA, "Acute middle cerebral artery occlusion treated by thrombectomy in a patient with myelodysplastic syndrome and severe thrombocytopenia", Journal of vascular and interventional neurology, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on abiraterone acetate (the active ingredients of Zytiga) and Zytiga (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.